Rating Change
HC Wainwright & Co. analysts reiterated a Buy rating on REGENXBIO Inc. (NASDAQ:RGNX) on June 24, 2026.
reiterateNASDAQ:RGNX
HC Wainwright & Co. Reiterates Buy Rating on REGENXBIO Inc. (RGNX)
Rating Change HC Wainwright & Co. analysts reiterated a Buy rating on REGENXBIO Inc. (NASDAQ:RGNX) on June 24, 2026.
Market Context
REGENXBIO Inc. operates in the Healthcare sector. The stock currently trades at $9.97 with a market capitalization of $651.0M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for REGENXBIO Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for REGENXBIO Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 24, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 22, 2026 | Leerink Partners | Outperform | N/A |
| Jun 22, 2026 | Baird | Outperform | N/A |
| Jun 05, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 15, 2026 | B of A Securities | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View RGNX Stock Page
Frequently Asked Questions
What does a Buy rating mean for RGNX?
A Buy rating from HC Wainwright & Co. reflects the analyst's outlook on REGENXBIO Inc. (NASDAQ:RGNX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RGNX forecast page.